modelA07EC01
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Sulfasalazine | |
| ATC code: | A07EC01 | route: | oral |
| compartments: | 1 | |
| dosage: | 2000 | mg |
| volume of distribution: | 7.5 | L |
| clearance: | 0.341 | L/h |
| other parameters in model implementation | ||
Sulfasalazine is an anti-inflammatory and immunomodulatory drug composed of sulfapyridine and 5-aminosalicylic acid linked by an azo bond. It is primarily used for the treatment of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease, and also for rheumatoid arthritis. Sulfasalazine is approved and widely used today.
Pharmacokinetics
Pharmacokinetics reported in healthy adult volunteers after single oral dose.
References
Klotz, U (1995). [5-aminosalicylic acid and chronic inflammatory bowel diseases in children]. Klinische Padiatrie 207(5) 285–287. DOI:10.1055/s-2008-1046553 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7500605
Ma, JJ, et al., & Yao, X (2009). Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. Clinica chimica acta; international journal of clinical chemistry 407(1-2) 30–35. DOI:10.1016/j.cca.2009.06.025 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19560446
Kuhn, UD, et al., & Blume, HH (2010). Phenotyping with sulfasalazine - time dependence and relation to NAT2 pharmacogenetics. International journal of clinical pharmacology and therapeutics 48(1) 1–10. DOI:10.5414/cpp48001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20040334
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)